DOI:
10.1055/s-00000075
Seminars in Respiratory and Critical Care Medicine
LinksClose Window
References
Konstan MW, Döring G, Heltshe SL. et al; Investigators and Coordinators of BI Trial 543.45.
A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.
J Cyst Fibros 2014;
13 (02) 148-155
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.